ClinicalTrials.gg
CompletedNCT03035864Updated Apr 19, 2024Results posted

A 8 Weeks Study to Evaluate Efficacy & Safety of rhNGF vs Vehicle in Patients After Cataract and Refractive Surgery

A Phase 2 interventional study of rhNGF and Vehicle in Ocular Discomfort, sponsored by Dompé Farmaceutici S.p.A. Completed at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Dompé Farmaceutici S.p.A · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this exploratory study is to assess preliminary efficacy and safety of rhNGF when administered as eye drops to patients after cataract and refractive surgery.

The main criteria for evaluation were:

  • Change from baseline in SANDE scores for severity and frequency assessed at 8 weeks of treatment (primary efficacy endpoint)
  • Changes in Cornea vital staining with fluorescein (National Eye Institute [NEI] scales) assessed at 8 weeks of treatment (co-primary efficacy endpoint)
  • Changes in conjunctiva vital staining with fluorescein (NEI scales) (secondary efficacy endpoint);
  • Changes in Tear Film Break-Up Time (TFBUT)(secondary efficacy endpoint);
  • Changes in Cochet-Bonnet corneal aesthesiometry (secondary efficacy endpoint);
  • Changes in Nerve count and morphology at scanning laser in vivo corneal confocal microscopy (only patients who had Laser-Assisted In situ Keratomileusis [LASIK] surgery) (secondary efficacy endpoint);
  • Changes in SANDE scores (face values) for severity and frequency (secondary efficacy endpoint);
  • Incidence and frequency of treatment-emergent adverse events (TEAEs), assessed throughout the study (safety endpoint).
Read the detailed description

The proposed phase II study is a single-centre, randomized, double masked, parallel arm, vehicle-controlled trial, designed to evaluate the preliminary efficacy and safety of rhNGF eye drops at 20 µg/ml concentration administered six times daily for 8 weeks in patients who underwent cataract and corneal refractive surgery, both known to damage the corneal sensory nerve plexus.

After confirmation of inclusion and exclusion criteria all eligible patients will be randomized at 2:1 ratio to rhNGF or vehicle control treatment with 8 weeks of study treatments administration with 4 weeks Follow-up.

02

Conditions studied

  • Ocular Discomfort

Keywords

  • Ocular discomfort after cataract and refractive surgery
  • cataract surgery
  • refractive surgery
03

In context

Lead sponsor

Dompé Farmaceutici S.p.A is the lead sponsor of 52 studies on the registry; 4 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 18 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female ≥18 years old
  2. Patients who are characterized by the following clinical features:

    1. History of cataract or refractive corneal surgery in the study eye(s) in the previous 6 months;
    2. Mean Symptom Assessment in Dry Eye (SANDE) score for severity and frequency of at least 30 at baseline
  3. The same eye (study eye) must fulfill all the above criteria
  4. Best corrected distance visual acuity (BCDVA) score of ≥ 0.1 decimal units in both eyes at the time of study enrolment
  5. Female patients must have negative pregnancy urine test if at childbirth potential.
  6. Only patients who satisfy all requirements for may be included in the study. Written Informed Consent must be obtained before the initiation of any study-specific procedures.
  7. Patients must have the ability and willingness to comply with study procedures

Exclusion criteria

Exclusion Criteria:

  1. Any ocular disease other than Dry Eye requiring treatment with topical medications in either eye at the time of study enrolment.
  2. Any active ocular infection or active inflammation in either eye unrelated to Dry Eye.
  3. Presence or history of any systemic or ocular disorder, condition or disease (with particular attention to and neuro-oncological diseases) that could possibly interfere with the conduct of the required study procedures or the interpretation of the study results.
  4. Use of therapeutic or Refractive Contact lenses in either eye at the time of study enrolment;
  5. History of ocular surgery in the study eye(s), excluding corneal refractive or cataract procedures, within 90 days of study enrolment.
  6. Females of (those who are not surgically sterilized or for at least 1 year) are excluded from participation in the study if they meet any one of the following conditions:

    1. are currently pregnant or,
    2. have a positive result at the urine pregnancy test (Baseline/Day 0) or,
    3. intend to become pregnant during the study treatment period or,
    4. are breast-feeding or,
    5. are not willing to use highly effective measures, such as: hormonal contraceptives - oral, implanted, transdermal, or injected - and/or mechanical barrier methods - spermicide in conjunction with a barrier such as a condom or diaphragm or IUD (Intrauterine device) - during the entire course of and 30 days after the study treatment periods.
  7. Participation in another clinical study at the same time as the present and within 30 days of study enrolment;
  8. History of drug, medication or alcohol abuse or addiction.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
180 participants (actual)

Study arms

  • Experimental
    rhNGF 20 µg/ml

    Recombinant Human Nerve Growth Factor (rhNGF) at 20 μg/mL eye drops six times daily

    Drug: rhNGF

  • Placebo comparator
    Vehicle

    Vehicle eye drops six times daily

    Other: Vehicle

Interventions

06

What researchers measure

Primary outcomes

  1. Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment.

    The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

    Time frame: Baseline and Week 8

  2. Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)

    Corneal Staining was derived as the sum of scores of the five corneal sectors (central, superior, inferior, nasal, and temporal) each of which was scored on a scale of 0-3, with a minimum score of 0 and a maximal score of 15 (sum \> 3 out of 15 is abnormal).

    Time frame: Baseline and Week 8

Secondary outcomes

  1. Changes in Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)

    Conjunctival Staining was derived as the sum of scores of the conjunctival area (nasal-superior paralimbal, nasal-inferior paralimbal, nasal-peripheral, temporal-superior paralimbal, temporal-inferior paralimbal, temporal-peripheral) with a grading scale of 0-3 and with a minimum score of 0 and a maximal score of 18 (18 indicates the most abnormal score). Grades increase with the number and density of dots. Data for the main eye are reported.

    Time frame: From baseline to weeks 4, 8 and 12

  2. Changes in Tear Film Break-Up Time (TFBUT)

    The TFBUT measurement was performed after instillation of 5 microliters of 2% sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. Data for the main eye are reported.

    Time frame: From baseline to weeks 4, 8 and 12

  3. Changes in Cochet-Bonnet Corneal Aesthesiometry

    Corneal sensation was measured in both eyes in each of the four quadrants of the cornea using the Cochet Bonnet aesthesiometer before the instillation of any dilating or anesthetic eye drops. The handheld esthesiometer (Cochet-Bonnet) is a device that contains a thin, retractable, nylon monofilament that extends up to 6 cm in length. Variable pressure can be applied by the device by adjusting the length. The monofilament ranges from 60 mm to 5 mm and as the length is decreased the pressure increases from 11 mm/gm to 200 mm/gm. Data for the main eye are reported.

    Time frame: From baseline to week 8

  4. Changes in SANDE Scores (Face Values) for Frequency and Severity

    The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

    Time frame: From baseline to weeks 4, 8 and 12

07

Results

Posted Jul 22, 2019
Limitations and caveats
LImitations and caveats non specified

Participant flow

Eligible patients were randomized in a 2:1 ratio to rhNGF eye drops solution at 20 μg/ml (120 patients) or vehicle eye drops solution (60 patients) 6 times per day for 8 weeks, followed by 4 weeks of follow-up with no further treatment.

Treatment Period
Participant flow — Treatment Period
MilestonerhNGF 20 µg/mlVehicle
Started12060
Completed11659
Not completed41
Withdrew: Adverse event10
Withdrew: Other31
Follow-up Period
Participant flow — Follow-up Period
MilestonerhNGF 20 µg/mlVehicle
Started11659
Completed10555
Not completed114
Withdrew: Adverse event10
Withdrew: Lost to follow-up62
Withdrew: Physician decision10
Withdrew: Other32

Outcome measures

PrimaryChange From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment.

The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

Time frame:
Baseline and Week 8
Reported as:
Mean · score on a scale
Change From Baseline in SANDE Scores for Frequency and Severity Assessed at 8 Weeks of Treatment.
score on a scalerhNGF 20 µg/mlVehicle
Frequency-37.2 ± 24.85-35.7 ± 26.04
Severity-37.8 ± 27.20-37.3 ± 20.43
Statistical analysis
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.974 · Difference in ls means: -0.11 · 95% CI -6.85 to 6.63
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.399 · Difference in least square means: 2.88 · 95% CI -3.85 to 9.61
PrimaryChanges in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)

Corneal Staining was derived as the sum of scores of the five corneal sectors (central, superior, inferior, nasal, and temporal) each of which was scored on a scale of 0-3, with a minimum score of 0 and a maximal score of 15 (sum \> 3 out of 15 is abnormal).

Time frame:
Baseline and Week 8
Reported as:
Mean · score on a scale
Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)
score on a scalerhNGF 20 µg/mlVehicle
Changes in Cornea Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)-2.5 ± 2.11-2.2 ± 1.81
Statistical analysis
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.214 · Difference in least square means: 0.04 · 95% CI -0.02 to 0.10
SecondaryChanges in Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)

Conjunctival Staining was derived as the sum of scores of the conjunctival area (nasal-superior paralimbal, nasal-inferior paralimbal, nasal-peripheral, temporal-superior paralimbal, temporal-inferior paralimbal, temporal-peripheral) with a grading scale of 0-3 and with a minimum score of 0 and a maximal score of 18 (18 indicates the most abnormal score). Grades increase with the number and density of dots. Data for the main eye are reported.

Time frame:
From baseline to weeks 4, 8 and 12
Reported as:
Mean · units on a scale
Changes in Conjunctiva Vital Staining With Fluorescein (National Eye Institute [NEI] Scales)
units on a scalerhNGF 20 µg/mlVehicle
week 40.0 ± 0.000.0 ± 0.00
week 80.0 ± 0.000.0 ± 0.00
week 120.0 ± 0.000.0 ± 0.00
SecondaryChanges in Tear Film Break-Up Time (TFBUT)

The TFBUT measurement was performed after instillation of 5 microliters of 2% sodium fluorescein solution into the inferior conjunctival cul-de-sac of each eye. The patient was instructed to blink several times to thoroughly mix the fluorescein with the tear film. Data for the main eye are reported.

Time frame:
From baseline to weeks 4, 8 and 12
Reported as:
Mean · seconds
Changes in Tear Film Break-Up Time (TFBUT)
secondsrhNGF 20 µg/mlVehicle
week 42.5 ± 3.072.5 ± 2.37
week 81.9 ± 2.962.2 ± 2.67
week 122.3 ± 2.612.7 ± 2.72
SecondaryChanges in Cochet-Bonnet Corneal Aesthesiometry

Corneal sensation was measured in both eyes in each of the four quadrants of the cornea using the Cochet Bonnet aesthesiometer before the instillation of any dilating or anesthetic eye drops. The handheld esthesiometer (Cochet-Bonnet) is a device that contains a thin, retractable, nylon monofilament that extends up to 6 cm in length. Variable pressure can be applied by the device by adjusting the length. The monofilament ranges from 60 mm to 5 mm and as the length is decreased the pressure increases from 11 mm/gm to 200 mm/gm. Data for the main eye are reported.

Time frame:
From baseline to week 8
Reported as:
Mean · cm
Changes in Cochet-Bonnet Corneal Aesthesiometry
cmrhNGF 20 µg/mlVehicle
superior nasal-0.1 ± 0.31-0.2 ± 0.31
inferior nasal-0.2 ± 0.32-0.1 ± 0.64
superior temporal-0.2 ± 0.36-0.2 ± 0.34
inferior temporal-0.1 ± 0.410.0 ± 0.64
SecondaryChanges in SANDE Scores (Face Values) for Frequency and Severity

The Symptom Assessment in Dry Eye (SANDE) questionnaire is a short questionnaire to evaluate both dry eye intensity and frequency by using a 100 mm visual analogue scale (VAS). The patient symptoms of ocular dryness and/or irritation were quantified on the scale based on two questions that assessed both the severity and frequency of symptoms. The SANDE score is calculated by taking the square root of the product of the frequency of symptoms score and the severity of symptoms score. The SANDE scale ranges from 0 to 100 with 100 being the maximal amount of dry eye symptoms and 0 being the minimal amount of dry eye symptoms.

Time frame:
From baseline to weeks 4, 8 and 12
Reported as:
Mean · score on a scale
Changes in SANDE Scores (Face Values) for Frequency and Severity
score on a scalerhNGF 20 µg/mlVehicle
Frequency - week 4-35.1 ± 22.37-33.2 ± 25.18
Frequency - week 8-37.2 ± 24.84-35.7 ± 26.04
Frequency - week 12-42.1 ± 22.94-38.6 ± 26.25
Severity - week 4-35.7 ± 24.28-32.9 ± 20.03
Severity - week 8-37.9 ± 27.51-37.3 ± 20.43
Severity - week 12-43.5 ± 22.7-38.4 ± 20.23
Statistical analysis
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.881 · Difference in least square means: -0.43 · 95% CI -6.13 to 5.27
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.926 · Difference in least square means: -0.31 · 95% CI -6.96 to 6.33
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.426 · Difference in least square means: -2.29 · 95% CI -7.97 to 3.38
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.828 · Difference in least square means: 0.62 · 95% CI -5.04 to 6.29
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.394 · Difference in least square means: 2.86 · 95% CI -3.75 to 9.47
  • rhNGF 20 µg/ml vs Vehicle · ANCOVA · p = =0.552 · Difference in least square means: -1.49 · 95% CI -6.41 to 3.44

Adverse events

Collected over Adverse events were collected at each time point of the study (ie. Baseline visit, Week 4, Week 8 and week 12 (follow-up visit). Non-serious events are listed at a 0.9% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rhNGF 20 µg/ml0/115 (0%)1/115 (0.9%)50/115 (43.5%)
Vehicle0/59 (0%)0/59 (0%)19/59 (32.2%)
Most frequent serious events
Most frequent serious events
EventrhNGF 20 µg/mlVehicle
AppendicitisInfections and infestations1/1150/59
Most frequent other events
Showing 10 of 41
Most frequent other events
EventrhNGF 20 µg/mlVehicle
Eye painEye disorders23/1152/59
Eye irritationEye disorders13/11510/59
Vision blurredEye disorders7/11510/59
Dry eyeEye disorders6/1156/59
MyopiaEye disorders10/1154/59
HeadacheNervous system disorders9/1150/59
photophobiaEye disorders3/1153/59
Eye swellingEye disorders4/1152/59
Eyelid oedemaEye disorders3/1150/59
foreign body sensation in eyesEye disorders2/1151/59

Baseline characteristics

Analysed for safety (SAF) population

Age, Continuous
Age, Continuous(years)rhNGF 20 µg/mlVehicleTotal
Mean38.0 ± 12.8034.4 ± 11.2036.8 ± 12.36
Sex: Female, Male
Sex: Female, Male(Participants)rhNGF 20 µg/mlVehicleTotal
Female7133104
Male442670
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)rhNGF 20 µg/mlVehicleTotal
Hispanic or Latino022
Not Hispanic or Latino11557172
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)rhNGF 20 µg/mlVehicleTotal
Italy11559174
08

Study locations

1 site
  • Univ. G. D'Annunzio-Clinica Oftalmologica-Chieti
    Chieti, Italy
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2017 to primary completion in Sep 2017, 7 months.

Results were first posted in Jul 2019, 1 year 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 23, 2017
First posted
Jan 30, 2017
StartActual
Jan 12, 2017
Primary completionActual
Sep 4, 2017
CompletionActual
Sep 4, 2017
Results first posted
Jul 22, 2019
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03035864
Responsible party
Sponsor
First posted
Jan 30, 2017
Start date
Jan 12, 2017
Primary completion
Sep 4, 2017
Completion
Sep 4, 2017
Results posted
Jul 22, 2019
Last update
Apr 19, 2024

Study contacts

Leonardo Mastropasqua, MD
principal investigator · Univ. G. D'Annunzio- Clinica Oftalmologica Chieti

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Recombinant human nerve growth factor

Start the discussion